CYDX (Cyduct Diagnostics) EPS (Basic): $ (TTM As of . 20)


What is Cyduct Diagnostics EPS (Basic)?

Cyduct Diagnostics CYDX +4.22% EPS (Basic) is $ as of . 20.

Cyduct Diagnostics's basic earnings per share (Basic EPS) for the three months ended in . 20 was $0.00. Cyduct Diagnostics does not have enough years/quarters to calculate its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in . 20.

Cyduct Diagnostics's EPS (Diluted) for the three months ended in . 20 was $0.00. Cyduct Diagnostics does not have enough years/quarters to calculate its EPS (Diluted) for the trailing twelve months (TTM) ended in . 20.

Cyduct Diagnostics's EPS without NRI for the three months ended in . 20 was $0.00. Cyduct Diagnostics does not have enough years/quarters to calculate its EPS without NRI for the trailing twelve months (TTM) ended in . 20.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Cyduct Diagnostics  (OTCPK:CYDX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cyduct Diagnostics EPS (Basic) Related Terms

Cyduct Diagnostics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Cyduct Diagnostics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyduct Diagnostics EPS (Basic) Chart

Cyduct Diagnostics Annual Data
Trend
EPS (Basic)

Cyduct Diagnostics Quarterly Data
EPS (Basic)

Cyduct Diagnostics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Cyduct Diagnostics's Basic EPS for the fiscal year that ended in . 20 is calculated as

Basic EPS (A: . 20 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-)/0
=

Cyduct Diagnostics's Basic EPS for the quarter that ended in . 20 is calculated as

Basic EPS (Q: . 20 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-)/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $ mean?
Cyduct Diagnostics (CYDX) has a EPS (Basic) of $ as of . 20. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Cyduct Diagnostics and its competitors.
Is Cyduct Diagnostics' EPS (Basic) too high?
Cyduct Diagnostics' current EPS (Basic) is $.
How does Cyduct Diagnostics' EPS (Basic) compare to SECI and QTXB?
Cyduct Diagnostics' EPS (Basic) of $ can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Devices & Instruments company?
A good EPS (Basic) depends on the Medical Devices & Instruments industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Cyduct Diagnostics and its competitors. Cyduct Diagnostics's current EPS (Basic) is $. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyduct Diagnostics stock overvalued right now?
Cyduct Diagnostics (CYDX) has a current EPS (Basic) of $. The current EPS (Basic) is $. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Cyduct Diagnostics (CYDX), the current EPS (Basic) is $ as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cyduct Diagnostics Business Description

Address 1698 Post Road East, Suite 1A, Westport, CT, USA, 06880
Cyduct Diagnostics Inc is a clinical-stage diagnostic company. It focuses on creating and enhancing a portfolio of technologies and assets based on the early assessment and detection of Breast Cancer. Its technology platform of MammoView devices is a single-use, high-margin product that assesses, screens, detects, monitors, and facilitates the treatment of identifiable changes that distinguish variations in breast health. The company markets these products under its Solos Endoscopy brand, along with a line of branded surgical instruments, manufactured by third parties to its design specifications, mainly endoscopes and hand-held surgical instruments for the minimally invasive surgery market.